Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poly-DA
- Development stage
- Preclinical
- Lead developer
- ITL Pharma
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Poly-DA is a polydopamine-based nanoparticle therapeutic candidate being developed by ITL Pharma for the treatment of Alzheimer's disease. Polydopamine is a synthetic, biocompatible polymer inspired by the adhesive proteins of mussels, known for its potent intrinsic antioxidant properties. In the context of Alzheimer's disease, Poly-DA is designed to function as a multi-functional neuroprotective agent that scavenges reactive oxygen species (ROS) and potentially inhibits the aggregation of amyloid-beta plaques. By mitigating oxidative stress and interfering with protein misfolding, Poly-DA aims to slow the neurodegenerative processes associated with the progression of the disease. It is part of ITL Pharma's proprietary polymer-based platform, which explores the therapeutic potential of polydopamine across various CNS and oncology indications.
- Other names
- polydopamine
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on Poly-DA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poly-DA.